Rani Therapeutics (NASDAQ:RANI) Issues Quarterly Earnings Results

Rani Therapeutics (NASDAQ:RANI) issued its quarterly earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03), Zacks reports. The firm had revenue of $1.03 million for the quarter.

Rani Therapeutics Trading Down 7.4 %

RANI opened at $1.26 on Tuesday. The company has a fifty day moving average price of $1.51 and a two-hundred day moving average price of $1.83. Rani Therapeutics has a 1-year low of $1.24 and a 1-year high of $8.75. The company has a market cap of $72.18 million, a P/E ratio of -1.19 and a beta of 0.14. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 2.34.

Wall Street Analysts Forecast Growth

RANI has been the topic of several recent analyst reports. Canaccord Genuity Group restated a “buy” rating and issued a $9.00 target price on shares of Rani Therapeutics in a report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Rani Therapeutics in a research report on Friday, February 7th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Rani Therapeutics has an average rating of “Buy” and a consensus price target of $12.33.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.